PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence

Documenti analoghi

• Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150
  di: Yue Zhou, et al.
  Pubblicazione: (2024)
• Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%
  di: Saadettin Kilickap, et al.
  Pubblicazione: (2025)
• Efficacy of immune checkpoint inhibitors according to programmed cell death‐ligand 1 expression in patients with non‐small cell lung cancer and brain metastasis: A real‐world prospective observational study
  di: Takeshi Masuda, et al.
  Pubblicazione: (2024)
• Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer
  di: Xiaonan Shi, et al.
  Pubblicazione: (2024)
• Long‐term survival of a patient with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) and untreated multiple brain metastases treated with zorifertinib: A case report
  di: Kang Li, et al.
  Pubblicazione: (2024)